RT Book, Section
A1 Lau, S.W. Johnny
A1 Cheung, Lily K.
A1 Chow, Diana Shu-Lian
A2 Shargel, Leon
A2 Yu, Andrew B.C.
SR Print(0)
ID 1117902332
T1 Application of Pharmaco­kinetics to Specific Populations: Geriatric, Obese, and Pediatric Patients
T2 Applied Biopharmaceutics & Pharmacokinetics, 7e
YR 2016
FD 2016
PB McGraw-Hill Education
PP New York, NY
SN 9780071830935
LK accesspharmacy.mhmedical.com/content.aspx?aid=1117902332
RD 2024/04/19
AB The  biggest  issue  in  PK/PD  and  drug  therapy  is  variability  in  response.*  Variability  factors  that  affect  pharmacokinetics  and  pharmacodynamics  influence  clinical  trials  and  dose  regimen  designs.  Early  in  drug  development,  the  term  “pharmacokinetics  in  disease  states”  was  used  to  describe  disease  factors  that  affect  PK.  This  term  is  concise  but  proved  inadequate  in  the  regulatory  and  clinical  environment.  The  term  “population”  pharmacokinetics  was  then  used  to  emphasize  that  the  PD  response  can  be  quite  different  dependent  on  the  demographic  of  the  subjects.  In  the  clinical  trial  and  labeling  environment,  the  term  “specific  populations”  may  be  used  to  convey  important  specific  medical  conditions  such  as  cancer  or  other  pathophysiologic  conditions  that  greatly  influence  the  patient’s  outcome.  The  terms  “specific”  and  “special”  have  been  used  in  different  occasions  referring  to  different  subject  populations  or  patient  conditions.